TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12004793

Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal coronary angioplasty (PTCA)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Coronary artery bypass surgery (CABG)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Physician work RVUs for PTCA
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Total RVUs for PTCA
Number of subjects: 2
Study: 9260697

Group type: EXPERIMENTAL
Intervention: Sclerotherapy
Number of subjects: 87

Group type: COMPARATOR
Intervention: Sham therapy
Number of subjects: 87
Study: 8494832

Group type: EXPERIMENTAL
Intervention: Midwife-led care
Number of subjects: 3510

Group type: COMPARATOR
Intervention: Consultant-led care
Number of subjects: 3510
Study: 3302875

Group type: EXPERIMENTAL
Intervention: Ceftriaxone (CFX) 1 g/24 h im
Number of subjects: 40

Group type: COMPARATOR
Intervention: Amikacin (AMK) 500 mg/24 h im
Number of subjects: 40
Study: 31992377

Group type: EXPERIMENTAL
Intervention: Betaine (BT) 0.6 g/kg DM without RPFA
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Betaine (BT) 0.6 g/kg DM with RPFA
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Betaine (BT) without RPFA
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: RPFA addition
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: RPFA or BT addition
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: BT addition
Number of subjects: 48
Study: 31270037

Group type: EXPERIMENTAL
Intervention: FFR-guided CABG
Number of subjects: 172

Group type: COMPARATOR
Intervention: Angiography-guided CABG
Number of subjects: 172
Study: 27138546

Group type: EXPERIMENTAL
Intervention: Rifampicin 10 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rifampicin 20 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rifampicin 100 mg
Number of subjects: 0
Study: 25040850

Group type: EXPERIMENTAL
Intervention: Affective statement expressing concern about the information
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Verbal reference to a written summary of the information
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Both affective qualifier and written summary
Number of subjects: 157

Group type: COMPARATOR
Intervention: Simple statement (control)
Number of subjects: 157
Study: 23381535

Group type: EXPERIMENTAL
Intervention: Comfort-oriented care (default option checked)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Life-extending care (default option checked)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Standard advance directive (no options checked)
Number of subjects: 132
Study: 21251180

Group type: EXPERIMENTAL
Intervention: LY 0.5/1.0
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: LY 1.0/1.0
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: LY 1.0/2.0
Number of subjects: 262
Study: 19297116

Group type: EXPERIMENTAL
Intervention: Computer agent explanation of consent form
Number of subjects: 0

Group type: COMPARATOR
Intervention: Human explanation of consent form
Number of subjects: 0

Group type: COMPARATOR
Intervention: Self-study condition
Number of subjects: 0
Study: 17194911

Group type: EXPERIMENTAL
Intervention: XELOX (intravenous oxaliplatin plus oral capecitabine; 3‐week cycle for eight cycles)
Number of subjects: 1864

Group type: EXPERIMENTAL
Intervention: XELOX
Number of subjects: 1864

Group type: COMPARATOR
Intervention: FU/LV (bolus fluorouracil/leucovorin)
Number of subjects: 1864
Study: 15537400

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy
Number of subjects: 0
Study: 12407272

Group type: EXPERIMENTAL
Intervention: Usual care management (N=31)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Enhanced care management (N=94)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Intensive care management (N=74)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Usual care management (N=192, previous year cohort)
Number of subjects: 31
Study: 9703588

Group type: EXPERIMENTAL
Intervention: APAP therapy
Number of subjects: 31

Group type: COMPARATOR
Intervention: CPAP therapy
Number of subjects: 31

Group type: COMPARATOR
Intervention: NPSG night
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: APAP applied pressure
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Maximum APAP applied pressure
Number of subjects: 31
Study: 8131529

Group type: EXPERIMENTAL
Intervention: Salbutamol administration
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo inhalation
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group (healthy parents of infants without bronchiolitis)
Number of subjects: 66
Study: 2683789

Group type: EXPERIMENTAL
Intervention: Nitrendipine
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 1101618

Group type: EXPERIMENTAL
Intervention: Etidocaine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bupivacaine
Number of subjects: 0
Study: 377470

Group type: EXPERIMENTAL
Intervention: Ketoprofen
Number of subjects: 40

Group type: COMPARATOR
Intervention: N-methyl-d-glucamine salt of indomethacin
Number of subjects: 40
Study: 31779693

Group type: EXPERIMENTAL
Intervention: Supervised progressive strength training and oral protein supplement during hospitalization and at home 3 days/week for 4 weeks after discharge
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Supervised progressive strength training and oral protein supplement
Number of subjects: 85
Study: 28109128

Group type: EXPERIMENTAL
Intervention: Benralizumab
Number of subjects: 200
Study: 25827594

Group type: EXPERIMENTAL
Intervention: Bolus whey protein (WP; 20 g)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Low-dose leucine-enriched essential amino acids (LEAA; 3 g, 40% leucine)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 16
Study: 23725233

Group type: EXPERIMENTAL
Intervention: Educational CPR video
Number of subjects: 56

Group type: COMPARATOR
Intervention: Narrative CPR
Number of subjects: 56
Study: 21518557

Group type: EXPERIMENTAL
Intervention: Experimental group (rapid steroid reduction to 10 mg/d)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (standard corticosteroid therapy)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Experimental group
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study: 19624581

Group type: COMPARATOR
Intervention: Continuous venovenous hemodiafiltration (CVVHDF)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Intermittent hemodialysis (IHD)
Number of subjects: 125

Group type: COMPARATOR
Intervention: CVVHDF
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: IHD
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 125
Study: 17596637

Group type: EXPERIMENTAL
Intervention: Intravenous methylprednisolone
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Plasma exchange
Number of subjects: 69
Study: 15801334

Group type: EXPERIMENTAL
Intervention: Atomoxetine
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study: 12066106

Group type: EXPERIMENTAL
Intervention: Progestin-only contraceptive methods
Number of subjects: 319

Group type: COMPARATOR
Intervention: Nonhormonal methods
Number of subjects: 319
Study: 9866771

Group type: EXPERIMENTAL
Intervention: Real-time bolus tracking using CARE Bolus software
Number of subjects: 79

Group type: COMPARATOR
Intervention: Fixed, preselected start delay of 80 s (Control)
Number of subjects: 79
Study: 7557557

Group type: EXPERIMENTAL
Intervention: Aspirin (150 mg/day)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Picotamide (450 mg/day)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Picotamide (900 mg/day)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Aspirin plus Picotamide (150 mg/day and 450 mg/day respectively)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 48
Study: 2709254

Group type: EXPERIMENTAL
Intervention: Gradual reintroduction to normal milk (slow regrade)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Immediate return to full-strength formula
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Rapid regrade to a hypoallergenic whey hydrolysate formula
Number of subjects: 68

Group type: COMPARATOR
Intervention: All groups (including control)
Number of subjects: 68
Study: 798576

Group type: EXPERIMENTAL
Intervention: Oxprenolol
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Methyldopa
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 51

Group type: COMPARATOR
Intervention: Normotensive controls
Number of subjects: 51
Study: 31782945

Group type: EXPERIMENTAL
Intervention: TIPS added to qSOFA (T-qSOFA)
Number of subjects: 821
Study: 30918121

Group type: EXPERIMENTAL
Intervention: Immediate PrEP (IMM)
Number of subjects: 239

Group type: COMPARATOR
Intervention: Deferred PrEP (DEF)
Number of subjects: 239

Group type: COMPARATOR
Intervention: Deferred PrEP (DEF) with self-reported diagnosis of syphilis, rectal chlamydia (CT) or rectal gonorrhoea (GC) in the previous 12 months
Number of subjects: 239

Group type: COMPARATOR
Intervention: Deferred PrEP (DEF) with receptive anal intercourse without a condom (ncRAI) with two or more partners in the previous 3 months
Number of subjects: 239

Group type: COMPARATOR
Intervention: Deferred PrEP (DEF) lacking both syphilis/rectal CT/GC and multiple ncRAI partners
Number of subjects: 239
Study: 28135751

Group type: EXPERIMENTAL
Intervention: Absorbable sutures
Number of subjects: 161

Group type: COMPARATOR
Intervention: Non-absorbable sutures
Number of subjects: 161
Study: 24652860

Group type: EXPERIMENTAL
Intervention: Aerobic Training (AT)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control
Number of subjects: 50
Study: 23258319

Group type: EXPERIMENTAL
Intervention: Standard parapatellar (SP) surgical approach
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Mini-parapatellar (MP) surgical approach
Number of subjects: 60
Study: 21241906

Group type: EXPERIMENTAL
Intervention: Plate-haptic acrylic IOL (Acri.Smart 46S)
Number of subjects: 40

Group type: COMPARATOR
Intervention: 3-piece loop-haptic acrylic IOL (Acri.Lyc 53N)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both IOLs
Number of subjects: 40
Study: 19473224

Group type: EXPERIMENTAL
Intervention: Individual art therapy sessions for 1 h/week (n = 20)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group (n = 21)
Number of subjects: 41
Study: 16984699

Group type: EXPERIMENTAL
Intervention: Intervention group (40 children completed the program)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 121

Group type: COMPARATOR
Intervention: Control group (155 children)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Non-participants in intervention (74 children)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Non-participants in intervention
Number of subjects: 121
Study: 15024499

Group type: EXPERIMENTAL
Intervention: Tourniquet released intraoperatively after prosthetic components settled and hemostasis done
Number of subjects: 76

Group type: COMPARATOR
Intervention: Tourniquet released after wound closure and compressive bandage applied
Number of subjects: 76
Study: 11829723

Group type: EXPERIMENTAL
Intervention: Deoxycholate or liposomal formulations of amphotericin B
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fluconazole
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Itraconazole
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Second-generation triazoles and echinocandins
Number of subjects: 0
Study: 9522136

Group type: EXPERIMENTAL
Intervention: haemodilution group
Number of subjects: 60

Group type: COMPARATOR
Intervention: control group
Number of subjects: 60
Study: 7857501

Group type: EXPERIMENTAL
Intervention: hypericum extract LI 160
Number of subjects: 72

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 72
Study: 2676609

Group type: EXPERIMENTAL
Intervention: Coumarin (1,2‐benzopyrone) daily oral dose of 50 mg
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 27
Study: 16792

Group type: EXPERIMENTAL
Intervention: Triazolam 0.5 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Methyprylon 300 mg
Number of subjects: 20
Study: 31964678

Group type: EXPERIMENTAL
Intervention: QbTest plus usual care
Number of subjects: 60

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 60
Study: 30686609

Group type: EXPERIMENTAL
Intervention: Gabapentin 600 mg
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study: 29999197

Group type: EXPERIMENTAL
Intervention: Abametapir lotion, 0.74%
Number of subjects: 704

Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 704
Study: 27603423

Group type: EXPERIMENTAL
Intervention: Parenteral oestrogen
Number of subjects: 900

Group type: COMPARATOR
Intervention: Total androgen blockade
Number of subjects: 900
Study: 24531755

Group type: EXPERIMENTAL
Intervention: Vitamin C-rich apple juice (VCR) - 60 mg/L vitamin C and 510 mg catechin equivalent/L
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Polyphenol-rich apple juice (PR) - 22 mg/L vitamin C and 993 mg catechin equivalent/L
Number of subjects: 20
Study: 23094031

Group type: EXPERIMENTAL
Intervention: Continuous blue light exposure (GOLite, Philips, 468 nm)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Caffeine (2*200 mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 20368553

Group type: EXPERIMENTAL
Intervention: Bevacizumab (10 mg/kg every 2 weeks) plus interferon alfa-2a (9 MIU subcutaneously three times a week)
Number of subjects: 649

Group type: COMPARATOR
Intervention: Interferon plus placebo
Number of subjects: 649

Group type: EXPERIMENTAL
Intervention: Bevacizumab plus IFN (postprotocol therapy including a tyrosine kinase inhibitor)
Number of subjects: 649

Group type: COMPARATOR
Intervention: IFN plus placebo (postprotocol therapy including a tyrosine kinase inhibitor)
Number of subjects: 649
Study: 17464455

Group type: EXPERIMENTAL
Intervention: PPI+H2RA group (roxatidine given)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: None+H2RA group (roxatidine given)
Number of subjects: 15

Group type: COMPARATOR
Intervention: None+None group (roxatidine not given)
Number of subjects: 15
Study: 15542794

Group type: EXPERIMENTAL
Intervention: Cold air challenge (CACh)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Dry air challenge (DACh)
Number of subjects: 40
Study: 12045046

Group type: EXPERIMENTAL
Intervention: Heidelberg Retina Tomograph I (HRT)
Number of subjects: 55
Study: 10372726

Group type: EXPERIMENTAL
Intervention: GnRH antagonist (Nal‐Glu; 150 microg/kg) during midfollicular phase (MFP)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: GnRH antagonist (Nal‐Glu; 150 microg/kg) during late follicular phase (LFP)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: GnRH antagonist (Nal‐Glu; 150 microg/kg) during midluteal phase (MLP)
Number of subjects: 19
Study: 7752180

Group type: EXPERIMENTAL
Intervention: Cigarette smoking without caffeine
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Coffee plus cigarette smoking
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo (abstention from smoking and caffeine)
Number of subjects: 6
Study: 2115446

Group type: EXPERIMENTAL
Intervention: Rectal solution (100 mg flecainide)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Oral solution (100 mg flecainide)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Tablet (100 mg flecainide)
Number of subjects: 7
Study: 7002205

Group type: EXPERIMENTAL
Intervention: Ritodrine (long infusion)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ritodrine (short infusion)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ritodrine (intramuscular injection)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard treatment (bed rest and sedatives)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ritodrine (all regimens)
Number of subjects: 0
Study: 30693742

Group type: EXPERIMENTAL
Intervention: Nursing intervention
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional nursing care
Number of subjects: 100
Study: 28864689

Group type: EXPERIMENTAL
Intervention: Managed aquifer recharge (MAR) water consumption
Number of subjects: 16

Group type: COMPARATOR
Intervention: Brackish groundwater
Number of subjects: 16
Study: 25935174

Group type: EXPERIMENTAL
Intervention: IVUS-guided PCI
Number of subjects: 123

Group type: COMPARATOR
Intervention: Control group (angiography-guided PCI)
Number of subjects: 123
Study: 24347261

Group type: EXPERIMENTAL
Intervention: Blunt technique
Number of subjects: 1076

Group type: COMPARATOR
Intervention: Sharp technique
Number of subjects: 1076
Study: 21416547

Group type: EXPERIMENTAL
Intervention: Submandibular salivary gland transfer (SGT)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Oral pilocarpine
Number of subjects: 69
Study: 19716007

Group type: EXPERIMENTAL
Intervention: Topical sucralfate
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study: 17729016

Group type: EXPERIMENTAL
Intervention: Modafinil (100-400 mg/day or 200 mg/day)
Number of subjects: 348

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 348
Study: 15269315

Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Number of subjects: 141

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Valacyclovir
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Methylprednisolone plus valacyclovir
Number of subjects: 141
Study: 12167574

Group type: EXPERIMENTAL
Intervention: Cisplatin and 5-Fluorouracil chemotherapy (pulse regimen)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Cisplatin and 5-Fluorouracil chemotherapy (continuous infusion regimen)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Surgery alone (historical control)
Number of subjects: 83
Study: 10474398

Group type: EXPERIMENTAL
Intervention: Home visit interventions by school nurses and bilingual teachers
Number of subjects: 0

Group type: COMPARATOR
Intervention: No intervention (comparison group)
Number of subjects: 0
Study: 7712759

Group type: EXPERIMENTAL
Intervention: Continuous infusion of famotidine (1.7 mg/hr for 24 hrs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bolus administration of famotidine (20 mg i.v. over 10 mins, every 12 hrs)
Number of subjects: 0
Study: 1506045

Group type: EXPERIMENTAL
Intervention: 2 mL of 16.5% immune serum globulin (ISG)
Number of subjects: 76

Group type: COMPARATOR
Intervention: 2 mL of normal saline
Number of subjects: 76
Study: 6522905

Group type: EXPERIMENTAL
Intervention: Proximal gastric vagotomy (PGV)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Proximal gastric vagotomy and pyloroplasty (PGV + P)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Total gastric vagotomy (TGV)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Total gastric vagotomy and pyloroplasty (TGV + P)
Number of subjects: 38
Study: 30439560

Group type: EXPERIMENTAL
Intervention: Engagement with attractive female peer on social media (n=56)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Engagement with family member on social media (n=62)
Number of subjects: 118
Study: 29851803

Group type: EXPERIMENTAL
Intervention: Laser acupuncture (LA) plus conventional treatment
Number of subjects: 200

Group type: COMPARATOR
Intervention: Sham laser acupuncture (LA without laser output) plus conventional treatment
Number of subjects: 200
Study: 26924099

Group type: EXPERIMENTAL
Intervention: Personalized reminder intervention (customized letter and personal telephone outreach)
Number of subjects: 256

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Cost-effectiveness of the intervention
Number of subjects: 256
Study: 24332934

Group type: EXPERIMENTAL
Intervention: Motivational cues every 2 hours with advice on how to improve activity, on top of real-time visual feedback.
Number of subjects: 15
Study: 22099477

Group type: EXPERIMENTAL
Intervention: Tamsulosin and standard analgesia
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo and standard analgesia
Number of subjects: 61
Study: 20606402

Group type: COMPARATOR
Intervention: High-dose adecatumumab (6 mg/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low-dose adecatumumab (2 mg/kg)
Number of subjects: 0
Study: 17500020

Group type: EXPERIMENTAL
Intervention: Oral co-trimoxazole for 3 months
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo for 3 months
Number of subjects: 20
Study: 16640635

Group type: EXPERIMENTAL
Intervention: Periosteal graft group (n = 15)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Bioabsorbable membrane group (n = 15)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study: 15012690

Group type: EXPERIMENTAL
Intervention: Aspirin 200 mg daily for 8 weeks
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg/day for 8 weeks
Number of subjects: 73
Study: 11058789

Group type: COMPARATOR
Intervention: Polymorphisms in the alpha-2 macroglobulin gene (5 bp deletion and G/A point mutation)
Number of subjects: 238

Group type: COMPARATOR
Intervention: Polymorphisms in the alpha-2 macroglobulin gene (5 bp deletion and G/A point mutation) combined with APOE varepsilon4 genotype
Number of subjects: 238
Study: 9304162

Group type: EXPERIMENTAL
Intervention: Thrombolytic treatment
Number of subjects: 605

Group type: COMPARATOR
Intervention: No thrombolytic treatment
Number of subjects: 605

Group type: EXPERIMENTAL
Intervention: CAVB presence
Number of subjects: 605
Study: 8471229

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 40

Group type: COMPARATOR
Intervention: Nicardipine
Number of subjects: 40
Study: 3578970

Group type: EXPERIMENTAL
Intervention: Pneumatic antishock garment (PASG)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Control group (no PASG)
Number of subjects: 201
Study: 30038198

Group type: EXPERIMENTAL
Intervention: Buzzy System with distraction cards
Number of subjects: 72

Group type: COMPARATOR
Intervention: Magic gloves
Number of subjects: 72
Study: 27874837

Group type: EXPERIMENTAL
Intervention: Spiritist Passe (SP)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 72

Group type: COMPARATOR
Intervention: No-SP group (nonspiritual therapy)
Number of subjects: 72
Study: 24553973

Group type: EXPERIMENTAL
Intervention: Oral Montelukast
Number of subjects: 60

Group type: COMPARATOR
Intervention: Inhaled Budesonide
Number of subjects: 60